ATE314367T1 - Substituierte azabicyclische einheiten zur krankheitsbehandlung (nikotinische acetylcholinrezeptor-antagonisten) - Google Patents

Substituierte azabicyclische einheiten zur krankheitsbehandlung (nikotinische acetylcholinrezeptor-antagonisten)

Info

Publication number
ATE314367T1
ATE314367T1 AT02764140T AT02764140T ATE314367T1 AT E314367 T1 ATE314367 T1 AT E314367T1 AT 02764140 T AT02764140 T AT 02764140T AT 02764140 T AT02764140 T AT 02764140T AT E314367 T1 ATE314367 T1 AT E314367T1
Authority
AT
Austria
Prior art keywords
units
receptor antagonists
acetylcholine receptor
nicotinic acetylcholine
disease treatment
Prior art date
Application number
AT02764140T
Other languages
English (en)
Inventor
E Jon Jacobsen
Daniel P Walker
Jason K Myers
David W Piotrowski
Vincent E Groppi Jr
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of ATE314367T1 publication Critical patent/ATE314367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02764140T 2001-04-19 2002-04-18 Substituierte azabicyclische einheiten zur krankheitsbehandlung (nikotinische acetylcholinrezeptor-antagonisten) ATE314367T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28495001P 2001-04-19 2001-04-19
US34890401P 2001-10-26 2001-10-26
PCT/US2002/008268 WO2002085901A1 (en) 2001-04-19 2002-04-18 Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists)

Publications (1)

Publication Number Publication Date
ATE314367T1 true ATE314367T1 (de) 2006-01-15

Family

ID=26962909

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02764140T ATE314367T1 (de) 2001-04-19 2002-04-18 Substituierte azabicyclische einheiten zur krankheitsbehandlung (nikotinische acetylcholinrezeptor-antagonisten)

Country Status (11)

Country Link
US (1) US6869946B2 (de)
EP (1) EP1389208B1 (de)
JP (1) JP2004526788A (de)
AR (1) AR035817A1 (de)
AT (1) ATE314367T1 (de)
CA (1) CA2439960A1 (de)
DE (1) DE60208366T2 (de)
ES (1) ES2254723T3 (de)
MX (1) MXPA03009644A (de)
PE (1) PE20021019A1 (de)
WO (1) WO2002085901A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US6852716B2 (en) * 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease
US6858613B2 (en) 2002-02-19 2005-02-22 Pfizer Inc. Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AU2003276919B2 (en) 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
WO2004052889A1 (en) * 2002-12-06 2004-06-24 Pharmacia & Upjohn Company Llc Compounds as radioligands for the diagnosis of disease
EP1587511A2 (de) * 2003-01-22 2005-10-26 Pharmacia & Upjohn Company LLC Behandlung von krankheiten mit alpha-7 nach rezeptoragonisten
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
PL1697378T3 (pl) 2003-12-22 2008-04-30 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzoizoksazole i 1,2-benzoizotiazole oraz ich wytwarzanie i zastosowania
US20050234095A1 (en) 2004-03-25 2005-10-20 Wenge Xie Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
JPWO2005099698A1 (ja) * 2004-04-15 2008-03-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化された４−アミノ−５−クロロ−Ｎ−［（１Ｒ，３ｒ，５Ｓ）−８−メチル−８−アザビシクロ［３．２．１］オクタ−３−イル］−２−［１−メチルブタ−２−インイルオキシ］ベンズアミド含有組成物
WO2006001894A1 (en) * 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
US7632831B2 (en) 2004-05-07 2009-12-15 Memory Pharmaceuticals Corporation 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
JP2008525464A (ja) 2004-12-22 2008-07-17 メモリー・ファーマシューティカルズ・コーポレイション α−７ニコチン性受容体リガンド並びにその製造及び使用
ATE482959T1 (de) * 2005-08-22 2010-10-15 Targacept Inc Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
JP5232374B2 (ja) * 2006-09-29 2013-07-10 関東化学株式会社 ２位に置換基を有する光学活性キヌクリジノール類の製造方法
JP5172124B2 (ja) * 2006-09-29 2013-03-27 関東化学株式会社 ２位に置換基を有する光学活性キヌクリジノール類の製造方法
JP2011516489A (ja) 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
EP2300012A4 (de) * 2008-05-23 2011-07-06 Univ South Florida Verfahren zur behandlung von peripherem sensorischem nervenverlust mit verbindungen mit nicotinsäure-acetylcholin-rezeptor-wirkung
TW201031664A (en) * 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CA2799744C (en) 2010-05-17 2020-01-28 Envivo Pharmaceuticals, Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
WO2012177263A1 (en) * 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
US10183938B2 (en) * 2014-12-16 2019-01-22 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors
CN109320510B (zh) * 2018-11-27 2021-04-27 江苏慧聚药业有限公司 一种马罗匹坦游离碱的制备方法
CN111793017B (zh) * 2019-04-04 2024-01-16 广东东阳光药业股份有限公司 一种内酰胺化合物的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3702324A (en) 1970-06-24 1972-11-07 Stanford Research Inst 3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines
US4093734A (en) 1975-11-03 1978-06-06 Boehringer Ingelheim Gmbh Amino-benzoic acid amides
FR2529548A1 (fr) 1982-07-02 1984-01-06 Delalande Sa Nouveaux derives de l'amino-3 quinuclidine, leur procede et leur application en therapeutique
US5175173A (en) 1983-12-22 1992-12-29 Sun Jung Hui Carboxamides useful as antiemetic or antipsychotic agents
US4593034A (en) 1984-04-06 1986-06-03 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
US4820715A (en) 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
US4870181A (en) 1985-02-04 1989-09-26 A. H. Robins Company, Incorporated Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2])octan-3-yl)aminobenzamides
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
EP0201165B1 (de) 1985-03-14 1994-07-20 Beecham Group Plc Arzneimittel zur Behandlung von Emesis
GB8520616D0 (en) 1985-08-16 1985-09-25 Beecham Group Plc Compounds
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
EP0235878A3 (de) 1986-01-16 1989-06-14 Beecham Group Plc Neue Verbindungen
US4717563A (en) 1986-03-05 1988-01-05 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs
NL8701682A (nl) 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
EP0272052B1 (de) 1986-12-16 1992-07-08 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Angstlösende N-(1-Azabicyclo[2.2.2)oct-3-yl)benzamide und -thiobenzamide
US5237066A (en) 1987-02-04 1993-08-17 Delande S.A. Enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their application in therapy
US4835162A (en) 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
GB8718345D0 (en) 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
US5206246A (en) 1987-10-16 1993-04-27 A. H. Robins Company, Incorporated Anxiolytic-R-n(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides
IE63474B1 (en) 1987-12-24 1995-04-19 Wyeth John & Brother Ltd Heterocyclic compounds
FR2625678B1 (fr) 1988-01-13 1991-06-07 Delalande Sa Agents anorexigenes a base de n-(quinuclidin-3-yl)-benzamides ou thiobenzamides
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE3810552A1 (de) 1988-03-29 1989-10-19 Sandoz Ag Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
ATE85217T1 (de) 1988-08-04 1993-02-15 Synthelabo Antischizophren-wirksame s-n-(1-azabicyclo (2.2.2.>oct-3-yl)benzamide und thiobenzamide.
EP0353371A1 (de) 1988-08-04 1990-02-07 Synthelabo Steigerung der Gedächtnisleistung durch R-N-(1-azabicyclo[2.2.2]oct-3-yl)Benzamide und Thiobenzamide
US4920227A (en) 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Benzobicyclic carboxamide 5-HT3 antagonists
US5290938A (en) 1989-09-15 1994-03-01 Chiron Laboratories A.S. Preparation of S-(-)- and R-(+)-N-(quinuclidinyl-3)-amide
GB8928837D0 (en) 1989-12-21 1990-02-28 Beecham Group Plc Pharmaceuticals
US5057519A (en) 1990-06-11 1991-10-15 Bristol-Myers Squibb Company 5-HT3 antagonists: use in reducing opiate tolerance
US5070095A (en) 1990-12-12 1991-12-03 A. H. Robins Company, Incorporated Substituted 4-(amidino)benzamides of 1-azabicyclo[2.2.2]octan-3- and -4-amine as gastric prokinetic, antiemetic, and anxiolytic agents
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
US5084460A (en) 1990-12-24 1992-01-28 A. H. Robins Company, Incorporated Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
AU1752792A (en) 1991-03-08 1992-10-06 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
US5273972A (en) 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
US5236931A (en) 1992-03-26 1993-08-17 A. H. Robins Company, Incorporated 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
AU694424B2 (en) 1993-03-08 1998-07-23 Merck & Co., Inc. Human neuronal nicotinic acetylcholine receptor compositionsand methods employing same
IL109451A0 (en) 1993-04-29 1994-07-31 Zeneca Ltd Heterocyclic derivatives
US5723103A (en) 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US6235745B1 (en) 1997-04-18 2001-05-22 Janssen Pharmaceutica N.V. Use of 5HT3, antagonists for promoting intestinal lavage
JP2003501022A (ja) 1999-05-27 2003-01-14 ファルマシア・アンド・アップジョン・カンパニー イオンチャネルコンダクタンスを測定するための方法およびその組成物
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
DE60208366D1 (de) 2006-02-02
JP2004526788A (ja) 2004-09-02
US20030055043A1 (en) 2003-03-20
DE60208366T2 (de) 2006-07-06
ES2254723T3 (es) 2006-06-16
MXPA03009644A (es) 2004-01-29
PE20021019A1 (es) 2002-11-13
WO2002085901A1 (en) 2002-10-31
US6869946B2 (en) 2005-03-22
EP1389208A1 (de) 2004-02-18
AR035817A1 (es) 2004-07-14
EP1389208B1 (de) 2005-12-28
WO2002085901A8 (en) 2003-12-24
CA2439960A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
ATE314367T1 (de) Substituierte azabicyclische einheiten zur krankheitsbehandlung (nikotinische acetylcholinrezeptor-antagonisten)
AU2003261392A8 (en) M3muscarinic acetylcholine receptor antagonists
FR14C0075I2 (fr) Antagonistes des recepteurs muscariniques de l'acetylcholine
DE60125937D1 (de) Wirbelsäulenimplantat für osteosynthesevorrichtung
IL188112A0 (en) Muscarinic acetylcholine receptor antagonists
PL1682142T3 (pl) Antagoniści muskarynowego receptora M₃ acetylocholiny
IL165871A0 (en) Substituted quinoline CCR5 receptor antagonists
IL157551A0 (en) Ccr5 antagonists useful for treating aids
ATE346043T1 (de) Il-8-rezeptorantagonisten
EP1449851A4 (de) Anti-il13 rezeptor alpha 1 neutralisierendes antikörper
EE200300400A (et) Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
IS8515A (is) Ný M3 múskarínasetýlkólínviðtakamótlyf
IL176078A0 (en) Novel m3 muscarinic acetylcholine receptor antagonists
IL157770A0 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
IL172822A0 (en) Muscarnic acetylcholine receptor antagonists
IL172911A0 (en) Muscarinic acetylcholine receptor antagonists
IL172912A0 (en) Muscarinic acetylcholine receptor antagonists
NO20026103D0 (no) 1-amino-alkylcycloheksaner som 5-HT3 og neuronal nikotinreseptorantagonister
AU2003267088A8 (en) Chemokine receptor antagonists as therapeutic agents
IL174846A0 (en) Muscarinic acetylcholine receptor antagonists
IS6818A (is) Histamín viðtaka mótlyf
DE60209885D1 (de) Crf receptor antagonisten
DE60134836D1 (de) Il-9 receptor-antagonisten
FR2831909B1 (fr) Plancher insonorise et procede de preparation de ce plancher
SE0003996D0 (sv) Receptorantagonister

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties